Research Goal Sample Clauses

Research Goal. The Genealogist is being hired to research the following:
Sample 1Sample 2
AutoNDA by SimpleDocs
Research Goal. The objective of this study was to define the relationship between circulating heme and the heme degradation pathway in ACS pathogenesis and severity by establishing a measurable biomarker that is predictive of severe ACS risk with the future goal to improve prognosis. If successful, then we would have identified a biomarker to facilitate early intervention and management of severe ACS, and thereby reduce morbidity and mortality in SCD. We tested our hypothesis that “Unscavenged circulating heme increases the risk of severe ACS in children with SCD” using 2 interrelated specific aims: [1]: To determine the association between plasma levels of individual heme degradation biomarkers; total plasma heme (TPH), plasma free heme (PFH), plasma HO-1, plasma Hemopexin (Hx) during ACS and compare with their corresponding plasma levels at steady state. [2]: To determine the association between each individual heme degradation biomarkers [total plasma heme (TPH), plasma free heme (PFH), plasma HO-1, and plasma Hemopexin (Hx)] with severe ACS. Our overall strategy was to study SCD patients admitted to the hospital with ACS to define the relationship between circulating free heme, markers of heme degradation and severe ACS, using a cross sectional study design. Eligible patients with a confirmed diagnosis of SCD and ACS were recruited from the three hospitals of Children’s Healthcare of Atlanta: Xxxxxxxx, Scottish-Rite and Xxxxxx Spalding, which provides care for over 1,800 children and adolescents with SCD in the metro Atlanta area. According to the National Acute Chest Syndrome Study Group, the incidence of ACS in our patient population is approximately 20%. Eligible SCD patients admitted to the hospital with ACS or who develop ACS during admission were enrolled on study for a 3-year period (2015-2018) in the HOP-ACS Study. Patients were recruited within 48 hours of ACS diagnosis and informed consent or assent (where applicable) was obtained to the HOP- ACS protocol approved by the Emory Institutional Review Board (IRB) [IRB00047246]. ACS was defined as a new pulmonary infiltrate detected by chest radiograph (CXR) and associated with any of the following symptoms alone or in combination; pain (particularly chest/back), fever, hypoxia and /or difficulty breathing. SCD patients admitted to the hospital with ACS or who develop ACS during admission from December, 2015 to 2018, were identified based on the following criteria:  Inclusion Criteria – A confirmed diagnosis of...
Sample 1
Research Goal. The general goal of this thesis is to address the extent to which the forms of officially planned abandonment and neglect described above are indeed potentially harmful and represent a recipe for the collapse of war survivors who have to struggle to repair their own lives amidst shattered families and communities. In particular, this study explores the ways in which war survivors, amidst the extreme legacies of war and the post-war official neglect of these legacies, have been able to make use of locally available and accessible resources to develop strategies to engage in and to attain reconciliation and healing. Furthermore, the effectiveness of some of these strategies is studied.
Sample 1
Research Goal. It is the intent of this thesis to evaluate the association of maternal mortality with seat belt use and motor vehicle crashes in pregnant women. Former Director-General of the World Health Organization, Xxx Xxxx- wook, April 2005: Mothers, newborn and children represent the well- being of a society and its potential for the future. Their health needs cannot be left unmet without harming the whole of society (World Health Report, 2005).
Sample 1
Research Goal. The goal of this research was to develop a framework for flexible SLA template creation based on consumerís QoS requirements.
Sample 1
Research Goal. The goal of the Parties’ research under this Agreement will be to generate data and results regarding the use of Codiak Licensed Know-How and of the Codiak Materials to (a) discover and research Exosome therapeutics that include Codiak Materials or Sarepta Materials and that are directed to the Research Targets and (b) generate data and results therefrom to help Sarepta assess whether to exercise a Sarepta Option hereunder, in each case, in accordance with the Research Plan.
Sample 1
Research Goal. The general goal of the COHERENO project is to map structures for successful collaboration between contractors and other supply actors that are involved in nearly zero-energy building (nZEB) single family home (SFH) renovations. To support this general goal, it is the goal of this work to detect most potential customer segments (of owner-occupants) for nZEB SFH renovations and to identify characteristics of customers (in this case innovators and early adopters) that are similar in ways relevant to business modelling (like for example for the definition of customer values).
Sample 1
AutoNDA by SimpleDocs

Related to Research Goal

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Commercial Milestones (a) Within [*****] calendar days after the end of the first Calendar Year in which aggregate annual Net Sales for that Calendar Year for the Licensed Product in the Territory reach any threshold indicated in the Commercial Milestone Events listed below, EverInsight shall notify VistaGen of the achievement of such Commercial Milestone Event and VistaGen shall invoice EverInsight for the corresponding non-refundable, non-creditable Milestone Payment set forth below and EverInsight shall remit payment to VistaGen within [*****] Business Days after the receipt of the invoice, as described in Section 8.6 (Currency; Exchange Rate; Payments). Annual Net Sales Milestones for Licensed Product Milestone Payments (in Dollars) (each a “Commercial Milestone Event”): (1). [*****] (2). [*****] (3). [*****] (4). [*****] (5). [*****] (b) For the purposes of determining whether a Net Sales Milestone Event has been achieved, Net Sales of Licensed Product(s) in the Territory shall be aggregated. For clarity, the annual Net Sales Milestone Payments set forth in this Section 8.3 (Commercial Milestones) shall be payable only once, upon the first achievement of the applicable Commercial Milestone Event, regardless of how many times such Commercial Milestone Event is achieved. (c) If a Commercial Milestone Event in Section 8.3 (Commercial Milestones) is achieved and payment with respect to any previous Commercial Milestone Event in Section 8.3 has not been made, then such previous Commercial Milestone Event shall be deemed achieved and EverInsight shall notify VistaGen within fifteen (15) calendar days of such achievement. VistaGen shall then invoice EverInsight for such unpaid previous Commercial Milestone Event(s) and EverInsight shall pay VistaGen such unpaid previous milestone payment(s) within thirty (30) Business Days of receipt of such invoice. (d) In the event that, VistaGen believes any Commercial Milestone Event under Section 8.3(a) has occurred but EverInsight has not given VistaGen the notice of the achievement of such Commercial Milestone Event, it shall so notify EverInsight in writing and shall provide to EverInsight data, documentation or other information that supports its belief. Any dispute under this Section 8.3(d) (Commercial Milestones - subsection (d)) that relates to whether or not a Commercial Milestone Event has occurred shall be referred to the JSC to be resolved in accordance with ARTICLE 3 (Governance) and shall be subject to resolution in accordance with Section 14.10 (Dispute Resolution). The Milestone Payments made for each Commercial Milestone Event shall be non-creditable and non-refundable.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Goal The goals of the Department’s grants are to: 1. Reduce delinquency, increase offender accountability, and rehabilitate juvenile offenders through a comprehensive, coordinated, community-based juvenile probation system;

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!